Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
78 papers
Compass Pathways reported early results from its first Phase 3 trial of synthetic psilocybin (COMP360) for treatment‑resistant depression. In 258 patients, the 25 mg dose showed a statistically significant improvement versus placebo on the MADRS depression scale at week 6 (a 3.6‑point difference, p < 0.001). The Data and Safety…
Researchers gave different psychedelic drugs to mice and found the drugs could reopen a window of brain plasticity used for learning social rewards. This reopened window went along with changes in a social hormone system in a key reward area of the brain and with changes in genes that control…
This observational study followed 98 people who microdosed psychedelics over six weeks and found that people reported better psychological functioning on days they took a microdose, but there was little evidence that those effects lasted into the next days. Among 63 people who completed formal tests before and after the…
This paper describes psychedelic-assisted psychotherapy, which means giving drugs like ketamine, MDMA, psilocybin, LSD or ibogaine together with guided therapy. The authors say this approach has shown promising safety and benefits so far, even for people who did not get better with usual treatments. They also argue that these therapies…
This review explains how the mushroom drugs psilocybin and psilocin are broken down in the body. Psilocybin is mainly a pro-drug that enzymes convert into the active compound psilocin. Psilocin is then further changed, and the main substance found in urine is psilocin-O-glucuronide, which matters for clinical and forensic testing.…
Microdosing means taking a very small, sub‑hallucinogenic amount of a psychedelic drug. Research so far is limited and mixed: some large observational studies report small-to-medium mood gains, but at least one randomized trial found no objective benefit. There is no standard definition of microdosing, potency and legality vary, and long‑term…
This paper reviews the recent comeback of psychedelic research and points out that much of that work borrows from indigenous healing traditions. The authors say Indigenous people, ethnic and racial minorities, women, and other marginalized groups are often left out of research and the mainstream story about psychedelic medicine. The…
Researchers collected and read 15 studies where patients described their own experiences with psychedelic treatments for mental disorders. These studies looked at about 180 patient accounts across different drugs and different illnesses. Even though the drugs and treatment settings were very different, many patients described similar helpful processes, such as…
This systematic review looked at how classic psychedelics (LSD, psilocybin, ayahuasca) change activity in the brain’s Default Mode Network (DMN). The studies commonly found an acute disruption of connectivity inside the DMN and more communication between other resting‑state brain networks during the drug experience. The authors note these DMN changes…
Researchers used a large prospective online survey to test whether psychedelic drug use changes people’s metaphysical beliefs. After psychedelic use, people tended to move away from physicalist or materialist views and toward panpsychism and fatalism. Except for fatalism, these shifts lasted for at least 6 months. The shifts were linked…
Researchers surveyed 886 people who attended guided psychedelic retreats to test a scale of shared, togetherness experiences called "communitas." They found that stronger communitas during ceremonies was linked to small but measurable increases in psychological wellbeing and social connectedness up to four weeks after the retreat. Good relationships with facilitators,…
Researchers around the world have started clinical studies again to see if psychedelic drugs can help treat serious mental health problems. This work picks up after research that stopped around the 1950s. Scientists are running controlled studies to test whether these substances can safely reduce problems like depression, anxiety, addiction…
